Business
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. The Company also announced the submission of a meeting request to the U.S. Food and Drug Administration (FDA) as the next step in the resolution of CRL issues. “Our immediate priorit
About this update from Milestone Pharmaceuticals Inc.
[{"type":"image","alt":"Milestone Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Milestone Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YgaHOGiuZH1uIXCqN0ZsAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c","width":300,"height":57}},"lazy":false},{"type":"text","content":"Resolution of CRL Manufacturing issues in progress - Type A meeting requested","length":77,"tagName":"p"},{"type":"text","content":"No clinical safety or efficacy concerns raised by FDA","length":53,"tagName":"p"},{"type":"text","content":"MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. The Company also announced the submission of a meeting request to the U.S. Food and Drug Administration (FDA) as the next step in the resolution of CRL issues.","length":365,"tagName":"p"},{"type":"text","content":"“Our immediate priority is to engage with the U.S. FDA in order to address the CMC-related issues raised in the CRL received for CARDAMYST as a treatment for PSVT,” said Joe Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We are confident we can work with the FDA to fully respond to the CRL and remain committed to the potential of CARDAMYST. If approved, it will be the first and only self-administered therapy for the rapid termination of episodes of PSVT.”","length":505,"tagName":"p"},{"type":"text","content":"First Quarter and Recent Program Updates","length":40,"tagName":"p"},{"type":"text","content":"Etripamil for Patients with PSVT","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CRL for CARDAMYST™ for PSVT received from FDA. In March 2025, Milestone received a CRL regarding its NDA for CARDAMYST, its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT). In the letter, the Agency highlighted two key Chemistry, Manufacturing and Controls (CMC) issues to be addressed: 1) additional information on ni...